DR-307 The prevalence of homologous recombination deficiency (HRD) in sarcoma and its role as biomarker for PARP-inhibitor therapy

Soft tissue sarcoma treatment options are limited and prognosis is generally poor. It was recently shown that both osteosarcoma and leiomyosarcoma show signatures of homologous recombination deficiency (HRD) in their DNA. HRD tumors are known for their sensitivity to DNA double-strand break-inducing drugs, such as platinum derivatives or PARP-inhibitors. However, for many other sarcoma subtypes the existence of such a signature of defects is still unknown. Identification of HRD in a wider cohort of sarcoma subtypes by WGS may lead to a possible new opportunity for targeted therapy in sarcomas.

Winan van Houdt, Netherlands Cancer Institute, the Netherlands